28 results
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
and viral diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative … . Upon receiving an MA, innovative medicinal products are generally entitled to receive eight years of data exclusivity and 10 years of market
6-K
EX-99.3
IMCR
Immunocore Holdings plc
7 Nov 23
Current report (foreign)
7:09am
Prize (the German Prix Galien) for best ‘Orphan Drug’ for KIMMTRAK, adding to the French award for best ‘Medicine in Innovative Therapeutics’ received
6-K
EX-99.1
IMCR
Immunocore Holdings plc
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
of diseases, including cancer, autoimmune and infectious diseases, and Gadeta B.V., an innovative clinical-stage biopharmaceutical company pioneering
6-K
EX-99.2
IMCR
Immunocore Holdings plc
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
-up where they may be treated per the investigator’s decision, including potential enrolment in other clinical trials. This innovative design
6-K
EX-99.3
IMCR
Immunocore Holdings plc
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
decision including other clinical trials. This innovative design effectively randomizes patients to “real world” treatment since clinical trials
6-K
EX-99.2
xjxxmg eb73
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
wbjwy
6 Jun 22
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic
4:21pm
6-K
EX-99.1
fl18mgq79iz
3 Jun 22
Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing Phase 1 study in advanced unresectable or metastatic skin cancers
4:05pm
6-K
EX-99.3
e1gjtzo0wyo81hl2e
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.1
3oggx
4 Apr 22
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
4:06pm
6-K
EX-99.1
kc50eypp
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am
6-K
EX-99.1
inmgt5hskw
26 Jan 22
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
4:29pm
6-K
EX-99.1
zo9sef3dbwg
7 Dec 21
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:10pm
6-K
EX-99.3
es9st zm71qg0e2
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.1
57u2cgg44cmquoo7amcy
24 Aug 21
Current report (foreign)
4:33pm
6-K
EX-99.3
mk01jk
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
20-F
tyxg k19i2jml
25 Mar 21
Annual report (foreign)
7:01am
424B4
4jk9tx0dp
8 Feb 21
Prospectus supplement with pricing info
8:36am
F-1/A
r0pfn 0oyboquvkklncb
3 Feb 21
Registration statement (foreign) (amended)
5:22pm